专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

CA3034876A1 ENDOGLYCOSIDASE MUTANTS FOR GLYCOPROTEIN REMODELING AND METHODS OF USING IT 未知
公开(公告)号：CA3034876A1
公开(公告)日：2018-03-01
申请号：CA3034876
申请日：2017-08-23
申请人： CHO PHARMA INC , ACADEMIA SINICA , LIN NAN HORNG
发明人： LIN NAN-HORNG , HUANG LIN-YA , SHIVATARE SACHIN , CHEN LI-TZU , WONG CHI-HUEY , WU CHUNG-YI , CHENG TING
IPC分类号： A61K38/47 , C12N9/24 , C12P21/02
摘要： A mutant of EndoS2 includes one or more mutations in the sequence of a wild-type EndoS2 (SEQ ID NO: 1), wherein the one or more mutations are in a peptide region located within residues 133-143, residues 177-182, residues 184-189, residues 221-231, and/or residues 227-237, wherein the mutant of EndoS2 has a low hydrolyzing activity and a high tranglycosylation activity, as compared to those of the wild-type EndoS2. A method for preparing an engineered glycoprotein using the mutant of EndoS2 includes coupling an activated oligosaccharide to a glycoprotein acceptor. The activated oligosaccharide is a glycan oxazoline.

2. 发明专利

CA3034876C ENDOGLYCOSIDASE MUTANTS FOR GLYCOPROTEIN REMODELING AND METHODS OF USING IT 未知
公开(公告)号：CA3034876C
公开(公告)日：2022-10-04
申请号：CA3034876
申请日：2017-08-23
申请人： CHO PHARMA INC , ACADEMIA SINICA , LIN NAN HORNG
发明人： LIN NAN-HORNG , HUANG LIN-YA , SHIVATARE SACHIN S , CHEN LI-TZU , WONG CHI-HUEY , WU CHUNG-YI , CHENG TING
IPC分类号： A61K38/47 , C12N9/24 , C12P21/02
摘要： A mutant of EndoS2 includes one or more mutations in the sequence of a wild-type EndoS2 (SEQ ID NO:1), wherein the one or more mutations are in a peptide region located within residues 133-143, residues 177-182, residues 184-189, residues 221-231, and/or residues 227-237, wherein the mutant of EndoS2 has a low hydrolyzing activity and a high transglycosylation activity, as compared to those of the wild-type EndoS2. A method for preparing an engineered glycoprotein using the mutant of EndoS2 includes coupling an activated oligosaccharide to a glycoprotein acceptor. The activated oligosaccharide is a glycan oxazoline.

3. 发明专利

AU2017315677A1 Endoglycosidase mutants for glycoprotein remodeling and methods of using it 未知
公开(公告)号：AU2017315677A1
公开(公告)日：2019-04-11
申请号：AU2017315677
申请日：2017-08-23
申请人： ACADEMIA SINICA , CHO PHARMA INC , LIN NAN HORNG
发明人： LIN NAN-HORNG , HUANG LIN-YA , SHIVATARE SACHIN S , CHEN LI-TZU , WONG CHI-HUEY , WU CHUNG-YI , CHENG TING
IPC分类号： A61K38/47 , C12N9/24 , C12P21/02
摘要： A mutant of EndoS2 includes one or more mutations in the sequence of a wild-type EndoS2 (SEQ ID NO: 1), wherein the one or more mutations are in a peptide region located within residues 133-143, residues 177-182, residues 184-189, residues 221-231, and/or residues 227-237, wherein the mutant of EndoS2 has a low hydrolyzing activity and a high tranglycosylation activity, as compared to those of the wild-type EndoS2. A method for preparing an engineered glycoprotein using the mutant of EndoS2 includes coupling an activated oligosaccharide to a glycoprotein acceptor. The activated oligosaccharide is a glycan oxazoline.

4. 发明专利

AU2017315677B2 Endoglycosidase mutants for glycoprotein remodeling and methods of using it 未知
公开(公告)号：AU2017315677B2
公开(公告)日：2021-03-11
申请号：AU2017315677
申请日：2017-08-23
申请人： ACADEMIA SINICA , CHO PHARMA INC
发明人： LIN NAN-HORNG , HUANG LIN-YA , SHIVATARE SACHIN S , CHEN LI-TZU , WONG CHI-HUEY , WU CHUNG-YI , CHENG TING
IPC分类号： A61K38/47 , C12N9/24 , C12P21/02
摘要： A mutant of EndoS2 includes one or more mutations in the sequence of a wild-type EndoS2 (SEQ ID NO: 1), wherein the one or more mutations are in a peptide region located within residues 133-143, residues 177-182, residues 184-189, residues 221-231, and/or residues 227-237, wherein the mutant of EndoS2 has a low hydrolyzing activity and a high tranglycosylation activity, as compared to those of the wild-type EndoS2. A method for preparing an engineered glycoprotein using the mutant of EndoS2 includes coupling an activated oligosaccharide to a glycoprotein acceptor. The activated oligosaccharide is a glycan oxazoline.

5. 发明专利

JP2014144958A Globo h and related anti-cancer vaccines with novel glycolipid adjuvants 有权
标题翻译： GLOBO H和相关的抗癌药物与新型甘露醇辅剂
公开(公告)号：JP2014144958A
公开(公告)日：2014-08-14
申请号：JP2014035431
申请日：2014-02-26
申请人： Academia Sinica , アカデミアシニカAcademia Sinica
发明人： WONG CHI-HUEY , WU CHUNG-YI , YU ALICE , YU JOHN
IPC分类号： A61K39/00 , A61K39/385 , A61K39/39 , A61P35/00
CPC分类号： A61K39/0011 , A61K2039/55511 , A61K2039/6037 , A61K2039/6081 , A61K2039/627 , C12N15/1137 , C12N2310/14
摘要： PROBLEM TO BE SOLVED: To provide: an immunogenic composition capable of high levels of immune responses immune-targeting glycolipid antigen Globo H, which is a tumor associated sugar chain; a cancer vaccine; and a method of treating cancer.SOLUTION: The invention relates to an immunogenic composition comprising: (a) a sugar chain such as Globo H or an immunogenic fragment thereof conjugated with a carrier protein comprising diphtheria toxin cross-reacting material 197 (DT-CRM 197) through a linker such as p-nitrophenol; and (b) an adjuvant with the following structure comprising a glycolipid capable of binding CD1d on a dendritic cell such as an α-galactosyl ceramide derivative.
摘要翻译：要解决的问题：提供：能够高水平免疫应答的免疫原性组合物免疫靶向糖脂抗原Globo H，其是肿瘤相关糖链; 癌症疫苗; 和一种治疗癌症的方法。解决方案：本发明涉及免疫原性组合物，其包含：（a）糖链，例如Globo H或其与包含白喉毒素交叉反应材料197（DT-CRM）的载体蛋白缀合的免疫原性片段 197）通过接头如对硝基苯酚; 和（b）具有以下结构的佐剂，其包含能够结合树突状细胞如α-半乳糖基神经酰胺衍生物上的CD1d的糖脂。

6. 发明专利

JP2011229528A Expression of penicillin binding protein, and application thereof to high throughput detecting of antibiotic 审中-公开
标题翻译：扁桃酸蛋白结合蛋白的表达及其对抗生素高通量检测的应用
公开(公告)号：JP2011229528A
公开(公告)日：2011-11-17
申请号：JP2011102306
申请日：2011-04-28
申请人： Academia Sinica , 中央研究院
发明人： CHENG TING-JEN RACHEL , MA CHE ALEX , CHENG WEI-CHIEH , WONG CHI-HUEY
IPC分类号： C12Q1/18 , A61K31/192 , A61K31/365 , A61K31/427 , A61P31/04 , A61P43/00 , C07K14/195 , C12N15/09 , C12P21/02 , C12Q1/48 , G01N33/15 , G01N33/50 , G01N33/573
CPC分类号： Y02A50/473 , Y02A50/475 , Y02A50/481
摘要： PROBLEM TO BE SOLVED: To provide a method for expressing and purifying full-length class A penicillin-binding protein from bacteria, and a high-throughput screening method for antibiotic using the protein.SOLUTION: The method of purifying full-length class A penicillin-binding protein includes: amplifying DNA sequence of full-length penicillin-binding protein from bacterial genomic DNA; cloning the DNA sequence into a vector; expressing the DNA sequence in a host cell to obtain a full-length penicillin-binding protein; solubilizing the protein with a detergent; and purifying the protein.
摘要翻译：待解决的问题：提供从细菌表达和纯化全长A类青霉素结合蛋白的方法，以及使用该蛋白质的抗生素的高通量筛选方法。解决方案：全长A类青霉素结合蛋白的纯化方法包括：从细菌基因组DNA扩增全长青霉素结合蛋白的DNA序列; 将DNA序列克隆到载体中; 在宿主细胞中表达DNA序列以获得全长青霉素结合蛋白; 用洗涤剂溶解蛋白质; 并纯化蛋白质。版权所有（C）2012，JPO＆INPIT

7. 发明专利

JP2009183277A Expression of penicillin binding protein, and application thereof to high throughput detecting of antibiotics 审中-公开
标题翻译：扁桃酸结合蛋白的表达及其对抗生素的高通量检测的应用
公开(公告)号：JP2009183277A
公开(公告)日：2009-08-20
申请号：JP2008178187
申请日：2008-07-08
申请人： Academia Sinica , 中央研究院
发明人： CHENG TING-JEN RACHEL , MA CHE ALEX , CHENG WEI-CHIEH , WONG CHI-HUEY
IPC分类号： C12P21/02 , C12N15/09 , C12Q1/18 , G01N33/15 , G01N33/50
CPC分类号： Y02A50/473 , Y02A50/475 , Y02A50/481
摘要： PROBLEM TO BE SOLVED: To provide a method for expressing and purifying a full-length class A type penicillin-binding protein from bacteria, and a high-throughput screening method of antibiotics using the protein.
SOLUTION: The method for preparing the purified full-length class A type penicillin-binding protein comprises: amplifying a DNA sequence of a full-length penicillin-binding protein from a genome DNA of the bacteria; cloning the DNA sequence to a vector; expressing the DNA sequence in the host cell and obtaining the full-length penicillin-binding protein; and solubilizing the protein by a surfactant and purifying the protein.
COPYRIGHT: (C)2009,JPO&INPIT
摘要翻译：待解决的问题：提供从细菌中表达和纯化全长A类青霉素结合蛋白的方法，以及使用该蛋白质的高通量筛选抗生素筛选方法。解决方案：制备纯化的全长A型青霉素结合蛋白的方法包括：从细菌的基因组DNA扩增全长青霉素结合蛋白的DNA序列; 将DNA序列克隆到载体上; 在宿主细胞中表达DNA序列，获得全长青霉素结合蛋白; 并通过表面活性剂溶解蛋白质并纯化蛋白质。版权所有（C）2009，JPO＆INPIT

8. 发明申请

WO2015026484A9 ANTIBODY-MEDIATED ANTI-TUMOR ACTIVITY INDUCED BY REISHI MUSHROOM POLYSACCHARIDES 审中-公开
标题翻译：由REISHI MUSHROOM POLYSACCHARIDES诱导的抗体介导的抗肿瘤活性
公开(公告)号：WO2015026484A9
公开(公告)日：2015-04-16
申请号：PCT/US2014048325
申请日：2014-07-26
申请人： ACADEMIA SINICA , WONG CHI-HUEY , WU CHUNG-YI , HSU HSIEN-YEH , LIAO SHIH-FEN , LIANG CHI-HUI
发明人： WONG CHI-HUEY , WU CHUNG-YI , HSU HSIEN-YEH , LIAO SHIH-FEN , LIANG CHI-HUI
IPC分类号： A61K31/715 , A61K31/736 , A61K36/074
CPC分类号： A61K39/0002 , A61K36/074 , A61K39/0011 , A61K2039/55572 , A61K2039/575
摘要： Immunogenic compositions, cancer vaccines and methods for treating cancer comprising FMS, the fucose-enriched polysaccharide fraction from Reishi F3, are provided. Compositions comprise fucose-enriched Reishi polysaccharide fraction (FMS) MW = ~35kDa, wherein the FMS is isolated by size-exclusion chromatography from Reishi F3, and the FMS comprises polysaccharides having primarily a backbone selected from 1,4-mannan and 1,6-a-galactan, wherein the backbone is linked to a terminal fucose-containing side-chain. Immunogenic compositions comprising glycolipid adjuvants are provided. Antibodies generated by immunogenic compositions disclosed herein bind cancer cells comprising antigens Globo H, Globo H, Gb3, Gb4, Gb5 (SSEA-3) and SSEA-4 on the cell surface.
摘要翻译：提供免疫原性组合物，癌症疫苗和治疗癌症的方法，其包括FMS，来自Reishi F3的岩藻糖富集的多糖部分。组合物包含岩藻糖富集的赖斯多糖级分（FMS）MW =〜35kDa，其中通过来自Reishi F3的大小排阻色谱分离FMS，并且FMS包含主要选自1,4-甘露聚糖和1,6 α-半乳聚糖，其中所述主链与含末端岩藻糖的侧链连接。提供包含糖脂佐剂的免疫原性组合物。由本文公开的免疫原性组合物产生的抗体结合细胞表面上包含抗原Globo H，Globo H，Gb 3，Gb 4，Gb 5（SSEA-3）和SSEA-4的癌细胞。

9. 发明申请

WO2010005735A3 COMPOSITIONS FOR INDUCING IMMUNE RESPONSES SPECIFIC TO GLOBO H AND SSEA3 AND USES THEREOF IN CANCER TREATMENT 审中-公开
标题翻译：诱导GLOBO H和SSEA3特异性免疫应答的组合物及其在癌症治疗中的应用
公开(公告)号：WO2010005735A3
公开(公告)日：2010-03-18
申请号：PCT/US2009047537
申请日：2009-06-16
申请人： ACADEMIA SINICA , YU ALICE L , YU JOHN , WONG CHI-HUEY
发明人： YU ALICE L , YU JOHN , WONG CHI-HUEY
IPC分类号： A61K31/716 , A61K31/164 , A61K31/7008 , A61P35/00
CPC分类号： A61K39/0011 , A61K2039/55511 , A61K2039/6037 , A61K2039/6081 , A61K2039/627 , C12N15/1137 , C12N2310/14
摘要： An immune composition containing Globo H or its fragment (e.g., SSEA3) and an adjuvant, e.g., a -GalCer, for eliciting immune responses against Globo H or its fragment and uses thereof in cancer treatment. Also disclosed is a method of treating cancer by inhibiting the activity of one of FUT1 and FUT2, both of which involve in Globo H biosynthesis.
摘要翻译：包含Globo H或其片段（例如SSEA3）和佐剂（例如，-GalCer）的免疫组合物，用于引发针对Globo H或其片段的免疫应答及其在癌症治疗中的用途。还公开了通过抑制FUT1和FUT2之一的活性来治疗癌症的方法，两者都涉及Globo H生物合成。

10. 发明申请

WO2008128207A1 ALPHA-GALACTOSYL CERAMIDE ANALOGS AND THEIR USE AS IMMUNOTHERAPIES 审中-公开
标题翻译： ALPHA-GALACTOSYL CERAMIDE ANALOGS及其作为免疫球蛋白使用
公开(公告)号：WO2008128207A1
公开(公告)日：2008-10-23
申请号：PCT/US2008060275
申请日：2008-04-14
申请人： ACADEMIA SINICA , WONG CHI-HUEY , YU ALICE , CHANG YA-JEN
发明人： WONG CHI-HUEY , YU ALICE , CHANG YA-JEN
IPC分类号： A61K8/42 , A61K8/00 , C07C235/80 , C07C237/10
CPC分类号： C07H15/26 , A61K8/68 , A61K2800/91 , A61Q17/005 , C07H15/06 , C07H15/18
摘要： The present disclosure relates to synthetic alpha-galactosyl ceramide (a-GalCer) analogs, and their use as immunotherapies. In one aspect, a method of activating a cytokine response in a subject includes administering an effective amount of a compound to a subject, wherein the subject has an adaptive immune system that includes a population of cells, the population including at least one lymphocyte and at least one antigen-presenting cell, and wherein the compound is represented by the structure of formula (1) wherein, n is 0 to 25; X is selected from O and S; R 1 is selected from H, CH 3 , and phenyl, where phenyl is optionally substituted with H, OH, OCH 3 , F, CF 3 , phenyl, phenyl-F, C 1 -C 6 alkyl, or C 2 -C 6 branched alkyl; R 2 is selected from OH and H; R 3 is selected from C 1 -C 15 alkyl, and phenyl, where phenyl is optionally substituted with H, OH, OCH 3 , F, CF 3 , phenyl, C 1 -C 6 alkyl, or C 2 -C 6 branched alkyl; R 4 is selected from OH, OSO 3 H, OSO 3 Na, and OSO 3 K; and R 5 is selected from CH 2 OH and CO 2 H; or a pharmaceutically acceptable salt thereof; forming a complex between the compound and the antigen-presenting cell, wherein the formation of the complex results in the activation of a receptor on the lymphocyte; and activating the lymphocyte to produce the cytokine response.
摘要翻译：本公开内容涉及合成的α-半乳糖神经酰胺（a-GalCer）类似物，以及它们作为免疫治疗的用途。一方面，在受试者中激活细胞因子应答的方法包括向受试者施用有效量的化合物，其中所述受试者具有包括细胞群的适应性免疫系统，所述群体包括至少一种淋巴细胞和至少一个抗原呈递细胞，并且其中所述化合物由式（1）的结构表示，其中n为0至25; X选自O和S; R 1选自H，CH 3和苯基，其中苯基任选被H，OH，OCH 3，F，CF 苯基，苯基-F，C 1 -C 6烷基或C 2 -C 6亚烷基 >支链烷基; R 2选自OH和H; R 3选自C 1 -C 15烷基和苯基，其中苯基任选被H，OH，OCH 3取代， 3，F，CF 3，苯基，C 1 -C 6烷基或C 2 H 2 -C 6 -C 6支链烷基; R 4选自OH，OSO 3 H，OSO 3 Na和OSO 3 K; 和R 5选自CH 2 OH和CO 2 H; 或其药学上可接受的盐; 在化合物和抗原呈递细胞之间形成复合物，其中复合物的形成导致淋巴细胞上受体的活化; 并激活淋巴细胞以产生细胞因子反应。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式